HOUSTON–(BUSINESS WIRE)–SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of Canadian Patent No. 2641170, “Methods And Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.” The technology described in the patent involves incorporating a matrix constructed of a synthetic polymer, a natural hydrogel, or a synthetic hydrogel to expose the fibroblasts to a mechanical strain using intermittent hydrostatic pressure and/or fluid shear stress. Other claims provide for growth factors such as BMP-2, BMP-4, BMP-6, BMP-7, transforming growth factor (TGF-β), and insulin growth factor (IGF-I).
“We are excited the Canadian Patent Office has recognized the uniqueness of our technology and this continues to build on our leading position in intellectual property surrounding the use of human dermal fibroblasts for tissue engineering which includes 12 U.S. and foreign patents issued and directly owned by the company, along with 38 patents pending,” said Pete O’Heeron, Chief Executive Officer for SpinalCyte.
About SpinalCyte, LLC
Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company founded for the purpose of developing an innovative solution for spinal nucleus replacement using human dermal fibroblasts. To date, SpinalCyte has been funded entirely by angel investors.
Pete O’Heeron, 281.461.6211